ReviewInternational journal of biological sciences2021
Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery.
Review in International journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Cyanobacterial and microalgae polymers: antiviral activity and applications.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Adverse drug reactions associated with COVID-19 management.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- The Evaluation of Drugs as Potential Modulators of the Trafficking and Maturation of ACE2, the SARS-CoV-2 Receptor.Biomolecules · 2024Article
- Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period.Signal transduction and targeted therapy · 2023Review
- Article
- The potential role of SARS-CoV-2 infection in acute coronary syndrome and type 2 myocardial infarction (T2MI): Intertwining spread.Immunity, inflammation and disease · 2023Review
- Article
- pH-dependent endocytosis mechanisms for influenza A and SARS-coronavirus.Frontiers in microbiology · 2023Review
- Pharmacological therapies and drug development targeting SARS-CoV-2 infection.Cytokine & growth factor reviews · 2022Review
- An Overview of Repurposed Drugs for Potential COVID-19 Treatment.Antibiotics (Basel, Switzerland) · 2022Review
- Review
- Overview of Hydroxychloroquine and Remdesivir on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Journal of heterocyclic chemistry · 2022Review
- Potential Antiviral Strategy Exploiting Dependence of SARS-CoV-2 Replication on Lysosome-Based Pathway.International journal of molecular sciences · 2022Review
- Anti-SARS-CoV-2 Inhibitory Profile of New Quinoline Compounds in Cell Culture-Based Infection Models.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Friend or Foe? Implication of the autophagy-lysosome pathway in SARS-CoV-2 infection and COVID-19.International journal of biological sciences · 2022Review
- Chloroquine and COVID-19-A systems biology model uncovers the drug's detrimental effect on autophagy and explains its failure.PloS one · 2022Article
- COVID-19 challenges and its therapeutics.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- The Effect of COVID-19 on NF-κB and Neurological Manifestations of Disease.Molecular neurobiology · 2021Review
- Misinformation on social networks during the novel coronavirus pandemic: a quali-quantitative case study of Brazil.BMC public health · 2021Article
- Clinical update on the use of mesenchymal stem cells in COVID-19.American journal of translational research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outbreak of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved into a global pandemic. One major challenge in the battle against this deadly disease is to find effective therapy. Due to the availability and proven clinical record of hydroxychloroquine (HCQ) and chloroquine (CQ) in various human diseases, there have been enormous efforts in repurposing these two drugs as therapeutics for COVID-19. To date, substantial amount of work at cellular, animal models and clinical trials have been performed to verify their therapeutic potential against COVID-19. However, neither lab-based studies nor clinical trials have provided consistent and convincing evidence to support the therapeutic value of HCQ/CQ in the treatment of COVID-19. In this mini review we provide a systematic summary on this important topic and aim to reveal some truth covered by the mystery regarding the therapeutic value of HCQ/CQ in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.